Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Anemia Associated with Chronic Renal Failure Condition: Patients on dialysis, not currently on Erythropoiesis-Stimulating Agent therapy |
Dose: Intravenous/Subcutaneous – 0.6 mcg/kg Frequency: every 2 weeks initially Note: Initiate treatment when hemoglobin level less than 10 g/dL. If hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt dose. Once hemoglobin has been stabilized, dose may be administered once monthly using a dose that is twice that of every-two-week dose and subsequently titrated as necessary. |
|
Indication: Anemia Associated with Chronic Renal Failure Condition: Patients not on dialysis, not currently on Erythropoiesis-Stimulating Agent therapy |
Dose: Intravenous/Subcutaneous – 0.6 mcg/kg Frequency: every 2 weeks initially Note: Consider initiating treatment only when hemoglobin level is less than 10 g/dL and the rate of hemoglobin decline indicates likelihood of requiring a red blood cell transfusion. If hemoglobin level greater than 10 g/dL, reduce or interrupt dose. Once hemoglobin has been stabilized, Mircera may be administered once monthly using a dose that is twice that of the every-two-week dose and subsequently titrated as necessary. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Safety and efficacy not established Note: Safety and efficacy not established |
Administration
- Give subcutaneously or IV
- Monitor hemoglobin levels
Side Effect
- Hypertension (13%)
- Diarrhea (11%)
- Nasopharyngitis (11%)
- Headache (9%)
- Upper respiratory tract infection (URTI) (9%)
- Cough (6%)
- Hypotension (5%)
- Urinary Tract Infection (UTI) (5%)
- Procedural arteriovenous fistula thrombosis (5%)
- Coronary artery disease
- Anemia
- Septic shock
- Serious cardiovascular and thromboembolic events
- Seizures
- Immunogenicity related PRCA
- Increased mortality and/or tumor progression in cancer patients
- Increased mortality
- Concomitant termination of other CRF therapy
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interaction studies have been performed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Uncontrolled hypertension
|
Risk of BP complications
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
This medicine should not be used after the expiry date (EXP) shown on the pack. Store in the refrigerator at 2°C to 8°C. Keep the pre-filled syringe in the outer carton in order to protect from light. Do not freeze. The patient may remove the product from refrigeration for storage at room temperature (not above 30°C) for one single period of 1 month. Once removed from the refrigerator the product must be used within this period.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.